QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
QQQ   444.84 (+0.00%)
AAPL   170.76 (-1.47%)
MSFT   420.78 (-0.15%)
META   488.94 (-1.00%)
GOOGL   150.75 (-0.08%)
AMZN   180.84 (+0.56%)
TSLA   176.62 (-1.79%)
NVDA   907.43 (+0.55%)
NIO   4.63 (-0.86%)
AMD   181.86 (+1.26%)
BABA   72.56 (+1.35%)
T   17.56 (+0.06%)
F   13.27 (+1.61%)
MU   118.43 (-0.60%)
CGC   9.78 (+2.41%)
GE   175.57 (-2.53%)
DIS   122.69 (+1.41%)
AMC   3.74 (-13.82%)
PFE   27.88 (+0.36%)
PYPL   66.85 (+0.42%)
XOM   115.51 (+0.47%)
NASDAQ:APVO

Aptevo Therapeutics (APVO) Stock Price, News & Analysis

$4.14
+0.08 (+1.97%)
(As of 11:27 AM ET)
Today's Range
$4.00
$4.40
50-Day Range
$4.01
$7.48
52-Week Range
$3.81
$92.62
Volume
90,712 shs
Average Volume
99,032 shs
Market Capitalization
$1.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Aptevo Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
5.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Aptevo Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($57.83) to ($55.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.30 out of 5 stars

APVO stock logo

About Aptevo Therapeutics Stock (NASDAQ:APVO)

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

APVO Stock Price History

APVO Stock News Headlines

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Aptevo Therapeutics Inc (AP8N.BE)
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Aptevo Therapeutics Inc (AP8N.DU)
Aptevo Therapeutics Inc (APVO)
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics GAAP EPS of -$0.50
Aptevo to Present at Bio-Europe Conference
Aptevo Therapeutics Inc
See More Headlines
Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APVO
Employees
40
Year Founded
2016

Profitability

Net Income
$-17,410,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.11 million
Book Value
$28.58 per share

Miscellaneous

Free Float
420,000
Market Cap
$1.81 million
Optionable
Not Optionable
Beta
4.93

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Marvin L. White (Age 62)
    President, CEO & Director
    Comp: $841.39k
  • Mr. Jeffrey G. Lamothe CA (Age 58)
    Executive VP & COO
    Comp: $722.51k
  • Ms. SoYoung Kwon J.D. (Age 55)
    LL.M., Senior VP, General Counsel, Business Development & Corporate Affairs
    Comp: $639.37k
  • Ms. Daphne L. Taylor (Age 58)
    Senior VP & CFO
  • Dr. Dirk Huebner M.D. (Age 60)
    Chief Medical Officer

APVO Stock Analysis - Frequently Asked Questions

Should I buy or sell Aptevo Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" APVO shares.
View APVO analyst ratings
or view top-rated stocks.

How have APVO shares performed in 2024?

Aptevo Therapeutics' stock was trading at $7.9640 at the beginning of 2024. Since then, APVO shares have decreased by 47.0% and is now trading at $4.22.
View the best growth stocks for 2024 here
.

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 28,900 shares, an increase of 725.7% from the February 29th total of 3,500 shares. Based on an average daily volume of 91,700 shares, the days-to-cover ratio is presently 0.3 days. Approximately 5.5% of the company's stock are short sold.
View Aptevo Therapeutics' Short Interest
.

When is Aptevo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our APVO earnings forecast
.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) posted its earnings results on Tuesday, November, 14th. The biotechnology company reported ($22.00) EPS for the quarter, topping the consensus estimate of ($28.16) by $6.16.

When did Aptevo Therapeutics' stock split?

Aptevo Therapeutics shares reverse split on Wednesday, March 6th 2024. The 1-44 reverse split was announced on Wednesday, March 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, March 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (1.39%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APVO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners